Bausch Health Companies (BHC) vs HUTCHMED (China) (HCM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Bausch Health Companies (BHC) has outperformed HUTCHMED (China) (HCM) over the past year, losing 3.8% versus a loss of 10.6%. Over five years, HCM leads with a -55.8% price change compared with -78.4% for BHC. HUTCHMED (China) is the larger company by market cap ($2.37 billion vs $2.28 billion), about 1.0 times the size.
On valuation, Bausch Health Companies trades at a lower forward P/E (1.5x vs 52.6x for HUTCHMED (China)).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BHC | HCM |
|---|---|---|
| Share price | $6.09 | $13.63 |
| Market cap | $2.28B | $2.37B |
| 1-day change | -1.06% | -4.54% |
| YTD return | -11.51% | +7.13% |
| 1-year return | -3.76% | -10.64% |
| 5-year return | -78.41% | -55.79% |
| P/E ratio (TTM) | — | 136.30 |
| Forward P/E | 1.45 | 52.58 |
| EPS (TTM) | $-2.95 | $0.10 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $548.51M |
| Revenue growth (YoY) | — | -12.96% |
| Net income (latest FY) | — | $456.91M |
| Gross margin | — | 38.68% |
| Operating margin | — | -7.14% |
| Net margin | — | 83.30% |
| 52-week high | $8.00 | $16.33 |
| 52-week low | $4.33 | $9.77 |
| Distance from 52-week high | -23.94% | -16.53% |
| Analyst consensus | hold | strong_buy |
| Avg. price target upside | +23.25% | +61.48% |
| Average volume | 3.24M | 67.70K |
| Shares outstanding | 373.99M | 173.81M |
| Employees | 20,300 | 1,790 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Bausch Health Companies
BHC stock →Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company.
Health Care · Biotechnology: Pharmaceutical Preparations · 20,300 employees
About HUTCHMED (China)
HCM stock →HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. It provides Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,790 employees
BHC vs HCM FAQ
Which is bigger, Bausch Health Companies or HUTCHMED (China)?
HUTCHMED (China) (HCM) is larger, with a market capitalization of $2.37B compared with $2.28B for Bausch Health Companies (BHC).
Which stock has performed better over the past year, BHC or HCM?
BHC returned -3.76% over the past 12 months, compared with -10.64% for HCM (price return, excluding dividends). Past performance does not predict future results.
Are Bausch Health Companies and HUTCHMED (China) in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.